The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Overactive Bladder (OAB) Therapeutics Market Outlook 2024

Global Overactive Bladder (OAB) Therapeutics Market Outlook 2024

Publishing Date : Nov, 2021

License Type :
 

Report Code : 1634356

No of Pages : 114

Ask Your Query

Synopsis
Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.

Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.

The global Overactive Bladder (OAB) Therapeutics market was valued at US$ 3194.5 million in 2020 and is expected to reach US$ 3585.5 million by the end of 2027, growing at a CAGR of 1.6% during 2021-2027.

This report focuses on Overactive Bladder (OAB) Therapeutics volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Overactive Bladder (OAB) Therapeutics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Overactive Bladder (OAB) Therapeutics Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Anticholinergic Agents
  • Beta-3 Adrenoreceptor Agonists

Segment by Application

  • Hosptial
  • Clinci
  • Other

By Region

  • North America (United States, Canada, Mexico)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, Other Regions)
  • Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)
  • South America (Brazil, Argentina, Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, U.A.E., South Africa, Other Regions)

By Company

  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer
  • Ferring
  • GlaxoSmithKline
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • Lanzhou Institute of Biological Products
  • Merck
  • ONO Pharmaceutical
  • Sanofi
  • Tengion
  • Teva Pharmaceutical Industries

Scope of the Overactive Bladder (OAB) Therapeutics Market Report

Report Metric

Details

Report Name

Overactive Bladder (OAB) Therapeutics Market

Market size in 2020

US$ 3194.5 Million

The revenue forecast in 2027

US$ 3585.5 Million

Growth Rate

CAGR of 1.6% from 2021 to 2027

Market size available for years

2020-2027

Forecast units

Value (USD) & Volume (Units)

Segments covered

Types, End-User / Applications, Companies, and Region

Report coverage

Revenue & volume forecast, company share, competitive landscape, growth factors, and trends

Geographic regions covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Index

1 Overactive Bladder (OAB) Therapeutics Market Overview
1.1 Product Overview and Scope of Overactive Bladder (OAB) Therapeutics
1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Anticholinergic Agents
1.2.3 Beta-3 Adrenoreceptor Agonists
1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Comparison by Application: (2021-2027)
1.3.2 Hosptial
1.3.3 Clinci
1.3.4 Other
1.4 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2016-2027
1.4.2 Global Overactive Bladder (OAB) Therapeutics Sales 2016-2027
1.4.3 Overactive Bladder (OAB) Therapeutics Market Size by Region: 2016 Versus 2021 Versus 2027

2 Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers
2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2016-2021)
2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites, Area Served, Product Type
2.5 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends
2.5.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue
2.5.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region
3.1 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.3.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country
3.3.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.4.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country
3.4.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Region
3.5.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region
3.5.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.6.1 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country
3.6.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.7.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country
3.7.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2021)
4.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2016-2021)
4.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2016-2021)

5 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Application
5.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2021)
5.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2016-2021)
5.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 Astellas Pharma
6.2.1 Astellas Pharma Corporation Information
6.2.2 Astellas Pharma Description and Business Overview
6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
6.2.5 Astellas Pharma Recent Developments/Updates
6.3 Hisamitsu Pharmaceutical
6.3.1 Hisamitsu Pharmaceutical Corporation Information
6.3.2 Hisamitsu Pharmaceutical Description and Business Overview
6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.3.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Ferring
6.5.1 Ferring Corporation Information
6.5.2 Ferring Description and Business Overview
6.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
6.5.5 Ferring Recent Developments/Updates
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments/Updates
6.7 Ion Channel Innovations
6.6.1 Ion Channel Innovations Corporation Information
6.6.2 Ion Channel Innovations Description and Business Overview
6.6.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
6.7.5 Ion Channel Innovations Recent Developments/Updates
6.8 Kwang Dong Pharmaceutical
6.8.1 Kwang Dong Pharmaceutical Corporation Information
6.8.2 Kwang Dong Pharmaceutical Description and Business Overview
6.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.8.5 Kwang Dong Pharmaceutical Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products
6.9.1 Lanzhou Institute of Biological Products Corporation Information
6.9.2 Lanzhou Institute of Biological Products Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 ONO Pharmaceutical
6.11.1 ONO Pharmaceutical Corporation Information
6.11.2 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.11.5 ONO Pharmaceutical Recent Developments/Updates
6.12 Sanofi
6.12.1 Sanofi Corporation Information
6.12.2 Sanofi Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
6.12.5 Sanofi Recent Developments/Updates
6.13 Tengion
6.13.1 Tengion Corporation Information
6.13.2 Tengion Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
6.13.5 Tengion Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates

7 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis
7.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics
7.4 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Overactive Bladder (OAB) Therapeutics Distributors List
8.3 Overactive Bladder (OAB) Therapeutics Customers

9 Overactive Bladder (OAB) Therapeutics Market Dynamics
9.1 Overactive Bladder (OAB) Therapeutics Industry Trends
9.2 Overactive Bladder (OAB) Therapeutics Growth Drivers
9.3 Overactive Bladder (OAB) Therapeutics Market Challenges
9.4 Overactive Bladder (OAB) Therapeutics Market Restraints

10 Global Market Forecast
10.1 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Type (2022-2027)
10.2 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Application (2022-2027)
10.3 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Overactive Bladder (OAB) Therapeutics Sales (Kg) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Overactive Bladder (OAB) Therapeutics Sales (Kg) Comparison by Application (2021-2027)
Table 3. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Overactive Bladder (OAB) Therapeutics Covered in This Study
Table 5. Global Overactive Bladder (OAB) Therapeutics Sales (Kg) of Key Manufacturers (2016-2021)
Table 6. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Overactive Bladder (OAB) Therapeutics Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites and Area Served
Table 11. Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2016-2021) & (Kg)
Table 16. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2016-2021)
Table 17. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2016-2021) & (Kg)
Table 19. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2016-2021)
Table 20. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2016-2021)
Table 22. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2016-2021) & (Kg)
Table 23. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2016-2021)
Table 24. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2016-2021) & (Kg)
Table 27. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2016-2021)
Table 30. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2016-2021) & (Kg)
Table 31. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2016-2021)
Table 32. Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2016-2021) & (Kg)
Table 35. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2016-2021)
Table 38. Global Overactive Bladder (OAB) Therapeutics Sales (Kg) by Type (2016-2021)
Table 39. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2021)
Table 40. Global Overactive Bladder (OAB) Therapeutics Revenue (Million US$) by Type (2016-2021)
Table 41. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2016-2021)
Table 42. Global Overactive Bladder (OAB) Therapeutics Price (USD/Kg) by Type (2016-2021)
Table 43. Global Overactive Bladder (OAB) Therapeutics Sales (Kg) by Application (2016-2021)
Table 44. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2021)
Table 45. Global Overactive Bladder (OAB) Therapeutics Revenue (Million US$) by Application (2016-2021)
Table 46. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2016-2021)
Table 47. Global Overactive Bladder (OAB) Therapeutics Price (USD/Kg) by Application (2016-2021)
Table 48. Allergan Corporation Information
Table 49. Allergan Description and Business Overview
Table 50. Allergan Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. Allergan Overactive Bladder (OAB) Therapeutics Product
Table 52. Allergan Recent Developments/Updates
Table 53. Astellas Pharma Corporation Information
Table 54. Astellas Pharma Description and Business Overview
Table 55. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product
Table 57. Astellas Pharma Recent Developments/Updates
Table 58. Hisamitsu Pharmaceutical Corporation Information
Table 59. Hisamitsu Pharmaceutical Description and Business Overview
Table 60. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product
Table 62. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 63. Pfizer Corporation Information
Table 64. Pfizer Description and Business Overview
Table 65. Pfizer Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. Pfizer Overactive Bladder (OAB) Therapeutics Product
Table 67. Pfizer Recent Developments/Updates
Table 68. Ferring Corporation Information
Table 69. Ferring Description and Business Overview
Table 70. Ferring Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. Ferring Overactive Bladder (OAB) Therapeutics Product
Table 72. Ferring Recent Developments/Updates
Table 73. GlaxoSmithKline Corporation Information
Table 74. GlaxoSmithKline Description and Business Overview
Table 75. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product
Table 77. GlaxoSmithKline Recent Developments/Updates
Table 78. Ion Channel Innovations Corporation Information
Table 79. Ion Channel Innovations Description and Business Overview
Table 80. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product
Table 82. Ion Channel Innovations Recent Developments/Updates
Table 83. Kwang Dong Pharmaceutical Corporation Information
Table 84. Kwang Dong Pharmaceutical Description and Business Overview
Table 85. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 86. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product
Table 87. Kwang Dong Pharmaceutical Recent Developments/Updates
Table 88. Lanzhou Institute of Biological Products Corporation Information
Table 89. Lanzhou Institute of Biological Products Description and Business Overview
Table 90. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 91. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product
Table 92. Lanzhou Institute of Biological Products Recent Developments/Updates
Table 93. Merck Corporation Information
Table 94. Merck Description and Business Overview
Table 95. Merck Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 96. Merck Overactive Bladder (OAB) Therapeutics Product
Table 97. Merck Recent Developments/Updates
Table 98. ONO Pharmaceutical Corporation Information
Table 99. ONO Pharmaceutical Description and Business Overview
Table 100. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 101. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product
Table 102. ONO Pharmaceutical Recent Developments/Updates
Table 103. Sanofi Corporation Information
Table 104. Sanofi Description and Business Overview
Table 105. Sanofi Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 106. Sanofi Overactive Bladder (OAB) Therapeutics Product
Table 107. Sanofi Recent Developments/Updates
Table 108. Tengion Corporation Information
Table 109. Tengion Description and Business Overview
Table 110. Tengion Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 111. Tengion Overactive Bladder (OAB) Therapeutics Product
Table 112. Tengion Recent Developments/Updates
Table 113. Teva Pharmaceutical Industries Corporation Information
Table 114. Teva Pharmaceutical Industries Description and Business Overview
Table 115. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (Kg), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 116. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product
Table 117. Teva Pharmaceutical Industries Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Overactive Bladder (OAB) Therapeutics Distributors List
Table 121. Overactive Bladder (OAB) Therapeutics Customers List
Table 122. Overactive Bladder (OAB) Therapeutics Market Trends
Table 123. Overactive Bladder (OAB) Therapeutics Growth Drivers
Table 124. Overactive Bladder (OAB) Therapeutics Market Challenges
Table 125. Overactive Bladder (OAB) Therapeutics Market Restraints
Table 126. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2022-2027) & (Kg)
Table 127. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Type (2022-2027)
Table 128. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 129. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Type (2022-2027)
Table 130. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2022-2027) & (Kg)
Table 131. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Application (2022-2027)
Table 132. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 133. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Application (2022-2027)
Table 134. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2022-2027) & (Kg)
Table 135. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Region (2022-2027)
Table 136. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 137. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Region (2022-2027)
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Overactive Bladder (OAB) Therapeutics
Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Share by Type in 2020 & 2027
Figure 3. Anticholinergic Agents Product Picture
Figure 4. Beta-3 Adrenoreceptor Agonists Product Picture
Figure 5. Global Overactive Bladder (OAB) Therapeutics Market Share by Application in 2020 & 2027
Figure 6. Hosptial
Figure 7. Clinci
Figure 8. Other
Figure 9. Global Overactive Bladder (OAB) Therapeutics Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Overactive Bladder (OAB) Therapeutics Market Size 2016-2027 (US$ Million)
Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales 2016-2027 (Kg)
Figure 12. Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 13. Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers in 2020
Figure 14. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players: Market Share by Revenue in 2020
Figure 16. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2016-2021)
Figure 18. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2020
Figure 19. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2016-2021)
Figure 20. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2020
Figure 21. U.S. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Taiwan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Vietnam Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. U.A.E Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Type (2016-2021)
Figure 46. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Application (2016-2021)
Figure 47. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Application in 2020
Figure 48. Revenue Share of Overactive Bladder (OAB) Therapeutics by Application (2016-2021)
Figure 49. Revenue Share of Overactive Bladder (OAB) Therapeutics by Application in 2020
Figure 50. Manufacturing Cost Structure of Overactive Bladder (OAB) Therapeutics
Figure 51. Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics
Figure 52. Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Latest Life Science Market Reports

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock